|
Dr. Karn is currently the Reinberger Professor of Molecular Biology and Chairman of the Department of Molecular Biology and Microbiology at the Case School of Medicine (Case Western Reserve University). Additionally, Dr. Karn is serving as the co-Director of the Case Center for AIDS research with Dr. Michael Lederman. Formerly, he was a member of the MRC AIDS Directed Programme Steering Committee and subsequently served on the MRC’s Physiological Medicine and Infectious Diseases Board. In 1997, Dr. Karn founded RiboTargets Holdings Plc. and served as the Chief Scientific Officer until 1999. Frank Bonsal and Philip Goelet were early investors in the company and David U’Prichard served on the Board of Directors. RiboTargets merged with British Biotechnology, Plc. and, subsequently, with Vernalis, Plc. Dr. Karn has been a consultant to numerous pharmaceutical and biotechnology companies, including CIBA-Geigy, Molecular Tool, Inc., Orchid Biosciences, Inc. and Therexsys. Additionally, he is currently a member of the Scientific Advisory Board of Dihedron Corp., a company that was founded by Drs. Goelet and Brenner. Dr. Karn is the author of over 80 scientific papers and eight patent families. He has been the Executive Editor of the Journal of Molecular Biology since 1989. He is currently a Full Member of the NIH AIDS Molecular and Cellular Biology Study Section. Dr. Karn received his BS from Yale College in 1972 and a PhD in Molecular Biology from Rockefeller University in 1976. Dr. Goelet studied with Drs. Karn and Brenner from 1979 to 1982 at the MRC Laboratory of Molecular Biology at Cambridge University. The three scientists have a long history of collaboration, which includes the development of four life sciences companies: Molecular Tool, Inc., RiboTargets Holdings Plc., Acidophil, LLC and Dihedron Corp. | 